Chimerix has reported that antiviral agent CMX157 has demonstrated favourable safety, tolerability and a good drug distribution profile in a Phase I clinical trial.
In addition, results from a series of preclinical studies have shown that CMX157 has highly potent in vitro activity against HIV, and potent in vitro activity against xenotropic murine leukaemia virus-related virus, a retrovirus recently associated with chronic fatigue syndrome.
The blinded and dose-escalation Phase I study enrolled healthy volunteers, who were randomised to receive single dose ranging from 25mg to 400mg of CMX157 or a standard dose of Viread – an antiviral agent approved for the treatment of HIV and chronic hepatitis B.
The results showed that CMX157 was well tolerated without any laboratory, vital sign or electrocardiogram changes, or adverse events.
In addition, the active antiviral, TFV-PP, was measurable in peripheral blood mononuclear cells from all patients following the single 400 mg dose of CMX157.